QUANTRO Therapeutics receives important Austrian research funding to further develop its platform for the discovery of novel cancer therapies
Austrian Research Promotion Agency FFG awards funding to QUANTRO to accelerate the next development phase of the company's proprietary research platform
QUANTRO Therapeutics GmbH, a pioneer in the development of novel transcription factor-targeted cancer therapies, announced that the company has received an 18-month research grant from the Austrian Research Promotion Agency (FFG). This will support a EUR 1.7 million research project to scale up and enable multi-target profiling capabilities through QUANTRO's industrial-scale technology platform. The FFG funding programmes are financed by the Republic of Austria - specifically the Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology (BMK) and the Federal Ministry of Labour and Economy (BMAW) - but also by participating federal states as well as companies and research organizations.
Symbol image
Computer-generated image
The QUANTRO platform is the first available patented technology that enables time-resolved transcriptomic profiling to identify modulators, activators or inhibitors of transcription factors and cell signaling targets by quantifying transcriptional activity with unprecedented precision and sensitivity.
QUANTRO has successfully conducted its first large screening campaigns with single and dual target assays using its novel transcriptomic research platform. The funding available under the FFG grant will enable it to take this to a new industrial level and increase throughput through miniaturization and automation and, most importantly, multiplexing: QUANTRO is well on its way to developing the first 10-target transcriptomic screens for the discovery of transcription factor targets, some of which were previously considered therapeutically inaccessible.
This extension of multiplexing capabilities to a high-throughput screening (HTS) technology defines a new paradigm in drug discovery by enabling the simultaneous screening of new drug candidates for multiple targets in a variety of disease-promoting pathways. The resulting data is analyzed using QUANTRO's proprietary bioinformatics suite to support the identification and validation of drug candidates for further investigation within internal drug discovery programs.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
